RxDoctor Payments Data

William Palmer, NP

Nurse Practitioner · Warner Robins, GANPI 1285161539

Payments from drug & device makers

$3,476in general payments, 2019–2025

Across 79 payments — averaging $44.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$891
  • AbbVie$522
  • Ascensia Diabetes Care US Inc.$480
  • Sun Pharmaceutical Industries Inc.$324
  • Johnson & Johnson$276
  • UCB, Inc.$226
  • plus $756 from 11 others

What the payments were for

  • Consulting fees$48014%
  • Food & beverage$2,74079%
  • Education$2567%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,476 in reported general payments places this provider in the 90th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$127,234
Medicare patients
499
Services billed
2,666

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab157$670,614
Humira(Cf) PenAdalimumab40$305,085
HumiraAdalimumab25$294,045
Cosentyx Sensoready (2 Pens)Secukinumab13$93,749
Tacrolimus80$12,188
Ketoconazole523$9,168
Clobetasol Propionate119$8,517
Pimecrolimus13$7,778
Calcipotriene45$5,489
Doxycycline Hyclate227$3,050
Mometasone Furoate114$2,119
Triamcinolone Acetonide285$2,048
Metronidazole37$2,024
Fluorouracil25$1,622
Tretinoin22$1,453

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira$522$294,04525 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Warner Robins

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →